[go: up one dir, main page]

ECSP15050110A - Derivados de triazina - Google Patents

Derivados de triazina

Info

Publication number
ECSP15050110A
ECSP15050110A ECIEPI201550110A ECPI201550110A ECSP15050110A EC SP15050110 A ECSP15050110 A EC SP15050110A EC IEPI201550110 A ECIEPI201550110 A EC IEPI201550110A EC PI201550110 A ECPI201550110 A EC PI201550110A EC SP15050110 A ECSP15050110 A EC SP15050110A
Authority
EC
Ecuador
Prior art keywords
triazine derivatives
compounds
following formula
relates
present
Prior art date
Application number
ECIEPI201550110A
Other languages
English (en)
Inventor
Thomas Allen Chappie
Patrick Robert Verhoest
Jamison Bryce Tuttle
Christopher John Helal
Bethany Lyn Kormos
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP15050110A publication Critical patent/ECSP15050110A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a una nueva clase de derivados de triazina, como se describen en la siguiente Fórmula I, en donde A, X, R1, R2, R3 y R4 son como se definen en la presente, y al uso de los compuestos como inhibidores de PDE10.
ECIEPI201550110A 2013-05-02 2015-11-30 Derivados de triazina ECSP15050110A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361818650P 2013-05-02 2013-05-02

Publications (1)

Publication Number Publication Date
ECSP15050110A true ECSP15050110A (es) 2017-08-31

Family

ID=50841902

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201550110A ECSP15050110A (es) 2013-05-02 2015-11-30 Derivados de triazina

Country Status (33)

Country Link
US (3) US8933224B2 (es)
EP (1) EP2991989B1 (es)
JP (1) JP6263606B2 (es)
KR (1) KR101770905B1 (es)
CN (1) CN105164134B (es)
AP (1) AP2015008843A0 (es)
AR (1) AR096161A1 (es)
AU (1) AU2014261070A1 (es)
BR (1) BR112015027760A8 (es)
CA (1) CA2910759C (es)
CL (1) CL2015003037A1 (es)
CR (1) CR20150591A (es)
CU (1) CU20150144A7 (es)
DK (1) DK2991989T3 (es)
DO (1) DOP2015000271A (es)
EA (1) EA027936B1 (es)
EC (1) ECSP15050110A (es)
ES (1) ES2637816T3 (es)
GE (1) GEP201706675B (es)
MA (1) MA38559B1 (es)
MD (1) MD20150103A2 (es)
MX (1) MX2015015163A (es)
NI (1) NI201500157A (es)
NZ (1) NZ712949A (es)
PE (1) PE20151940A1 (es)
PH (1) PH12015502462A1 (es)
SG (1) SG11201508201VA (es)
TN (1) TN2015000490A1 (es)
TW (1) TWI508966B (es)
UA (1) UA111696C2 (es)
UY (1) UY35547A (es)
WO (1) WO2014177977A1 (es)
ZA (1) ZA201508968B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA38559B1 (fr) * 2013-05-02 2018-04-30 Pfizer Dérivés d'imidazo-triazine utilisés comme inhibiteurs de la pde10
CA3031585A1 (en) 2016-09-09 2018-03-15 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
CN112839648B (zh) 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
WO2021080312A1 (ko) * 2019-10-21 2021-04-29 에스케이바이오팜 주식회사 인지 장애의 예방, 경감 또는 치료, 또는 인지 기능 향상을 위한 이미다조피리미딘 또는 이미다조트리아진 화합물의 용도
JP2025505163A (ja) * 2022-02-02 2025-02-21 ザ・カトリック・ユニヴェルシテイト・ルーバン Yap/taz-teadを阻害するためのテトラヒドロピリドピリミジン及び関連類似体
CN117486878A (zh) * 2023-10-27 2024-02-02 扬州市普林斯医药科技有限公司 一种恩那司他的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
CA2534432A1 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US20070167426A1 (en) 2004-06-02 2007-07-19 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
TW200716102A (en) 2005-06-01 2007-05-01 Wyeth Corp Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
US20080051419A1 (en) 2006-07-26 2008-02-28 Pfizer Inc. Amine derivatives useful as anticancer agents
WO2008041571A1 (en) 2006-09-26 2008-04-10 Kaneka Corporation Process for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
US20120004222A1 (en) 2007-08-21 2012-01-05 Zhicai Wu Cb2 receptor ligands for the treatment of pain
DE102007059723A1 (de) 2007-12-12 2009-06-18 Siemens Medical Instruments Pte. Ltd. Hörvorrichtung mit Batterieklappenmodul
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
US8404694B2 (en) 2008-03-20 2013-03-26 Amgen Inc. Aurora kinase modulators and method of use
KR101774035B1 (ko) * 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. 이미다조[1,2―b]피리다진 유도체 및 PDE10 저해제로서의 그의 용도
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
AR080754A1 (es) * 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2011141713A1 (en) 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
KR20130083389A (ko) 2010-05-28 2013-07-22 바이오크리스트파마슈티컬즈,인코포레이티드 야누스 키나아제 억제제로서 헤테로사이클릭 화합물
US20130085161A1 (en) 2010-06-17 2013-04-04 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
UA106692C2 (uk) 2011-02-23 2014-09-25 Пфайзер Інк. ІМІДАЗО[5,1-f][1,2,4]ТРИАЗИНИ ДЛЯ ЛІКУВАННЯ НЕВРОЛОГІЧНИХ РОЗЛАДІВ
MA38559B1 (fr) * 2013-05-02 2018-04-30 Pfizer Dérivés d'imidazo-triazine utilisés comme inhibiteurs de la pde10

Also Published As

Publication number Publication date
PE20151940A1 (es) 2016-01-21
MA38559B1 (fr) 2018-04-30
EP2991989B1 (en) 2017-06-28
EA201591819A1 (ru) 2016-05-31
BR112015027760A8 (pt) 2018-05-08
US20140329820A1 (en) 2014-11-06
DOP2015000271A (es) 2016-02-29
DK2991989T3 (en) 2017-07-31
EP2991989A1 (en) 2016-03-09
JP6263606B2 (ja) 2018-01-17
CU20150144A7 (es) 2016-04-25
KR101770905B1 (ko) 2017-08-23
CL2015003037A1 (es) 2016-04-22
KR20160003234A (ko) 2016-01-08
CA2910759C (en) 2018-01-16
CA2910759A1 (en) 2014-11-06
CN105164134A (zh) 2015-12-16
NI201500157A (es) 2015-11-30
PH12015502462A1 (en) 2016-02-22
ZA201508968B (en) 2017-11-29
US20150353579A1 (en) 2015-12-10
US9145427B2 (en) 2015-09-29
US8933224B2 (en) 2015-01-13
GEP201706675B (en) 2017-05-25
US9296761B2 (en) 2016-03-29
CN105164134B (zh) 2017-09-22
HK1213885A1 (zh) 2016-07-15
SG11201508201VA (en) 2015-11-27
TN2015000490A1 (fr) 2017-04-06
AP2015008843A0 (en) 2015-11-30
MD20150103A2 (ro) 2016-02-29
UA111696C2 (uk) 2016-05-25
EA027936B1 (ru) 2017-09-29
CR20150591A (es) 2016-01-04
ES2637816T3 (es) 2017-10-17
UY35547A (es) 2014-11-28
WO2014177977A1 (en) 2014-11-06
NZ712949A (en) 2017-04-28
AR096161A1 (es) 2015-12-09
AU2014261070A1 (en) 2015-10-29
TWI508966B (zh) 2015-11-21
US20150080401A1 (en) 2015-03-19
TW201506027A (zh) 2015-02-16
MX2015015163A (es) 2016-02-22
JP2016517877A (ja) 2016-06-20

Similar Documents

Publication Publication Date Title
DOP2017000267A (es) Amidas heterocíclicas como inhibidores de quinasa
DOP2018000089A (es) Amidas heterocíclicas como inhibidores de cinasas
MX2016004933A (es) Inhibidores de pirimidina del fgfr4.
CU24309B1 (es) Compuestos derivados tienopirimidina y composiciones farmacéuticas que los contienen
ECSP15050110A (es) Derivados de triazina
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
CR20140079A (es) Aminoquinazolinas como inhibidores de quinasa
UA116395C2 (uk) ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
MX2014002770A (es) Nuevos derivados dihidroquinolina-2-ona.
CR20150447A (es) Nuevos derivados de pirazol
CR20150250A (es) Nuevos derivados de piridina
MX2015009719A (es) Inhibidores benzoquinolona de vmat2.
CR20150440A (es) Nuevos derivados de piridina
DOP2015000059A (es) Amino-quinolinas como inhibidores de cinasa
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
EA201590688A1 (ru) Производные n-проп-2-инилкарбоксамида и их применение в качестве антагонистов trpa1
CR20150555A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina
PE20151145A1 (es) Piridopirazinas sustituidas como inhibidores de syk
CR20160146A (es) Derivados de urea indol sustituido con glucopiranosil y su uso como inhibidores sglt